EXHIBIT 99.1

                               VASO SHIPS PRODUCT

                  DANVERS, Mass. - (Business Wire) - July 28, 2006 - Vaso Active
Pharmaceuticals, Inc. ("Vaso Active") (VAPH.ob) announced today that it is has
shipped A-RExtreme(R) and Osteon(R) topical products that utilize its
proprietary PENtoCORE(R) technology, through its brokerage agreement with the
Ferolie Group of Montvale, New Jersey under purchase order to Pathmark Stores,
Inc. ("Pathmark"). Pathmark operates a 140 store supermarket chain in New
Jersey, New York, Pennsylvania and Delaware.

                  Vaso announced earlier this month that it has shipped products
utilizing its PENtoCORE technology under purchase order to Harmon Discount
Stores, a Bed Bath and Beyond subsidiary and to Kinray, Inc., a distributor of
pharmaceutical, health and beauty products to over 3,000 independent retailers
in the northeast.

                  "We are pleased to be moving forward with our strategy for
achieving distribution and market penetration with our PENtoCORE(R) line of
products." stated Joseph Frattaroli, President of Vaso Active.

         Vaso Active Pharmaceuticals, Inc, is an early stage company that
focuses on commercializing, marketing and selling over-the-counter
pharmaceutical products that incorporate either a patented transdermal
technology ("VALE") or a proprietary topical technology ("PENtoCORE").

         The unique VALE technology is intended to be a patchless, lipid-based
delivery system that uses an active process, incorporating chemical
vasodilators, to deliver drugs through the skin and into the bloodstream.
Products utilizing this technology are currently in development through
BioChemics, Inc.

         The PENtoCORE technology is a topical formulation and the Company is
currently marketing three products that incorporate this technology: OSTEON (for
temporary relief from minor arthritis pain), A-R EXTREME (for temporary relief
from minor muscle and joint pain associated with athletic activity) and TERMIN8
(for athlete's foot fungal infections).




FORWARD-LOOKING STATEMENTS
Certain statements contained herein constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on current expectations, estimates
and projections about the Company's industry, management's beliefs and certain
assumptions made by management. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are difficult to
predict. Because such statements involve risks and uncertainties, the actual
results and performance of the Company may differ materially from the results
expressed or implied by such forward-looking statements. Given these
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Unless otherwise required by law, the Company also
disclaims any obligation to update its view of any such risks or uncertainties
or to announce publicly the result of any revisions to the forward-looking
statements made here; however, readers should review carefully reports of
documents the Company files periodically with the SEC.

                  Contact:
Matt Carter
Vaso Active Pharmaceuticals, Inc.
978-750-1991 Ext. 28
         mcarter@vasoactive.us